Pfenex Inc. has earned a $15 million development milestone under its development and license agreement with Jazz Pharmaceuticals plc. The milestone is associated with process development activities for PF745, a long-acting Erwinia asparaginase. Under the agreement, Pfenex is eligible to receive a total of as much as $224.5 million in development and sales milestones. Pfenex is still eligible to receive $162.5 million, including up to $3.5 million for development milestones, $34 million in reg...